
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is a strong player in the healthcare market, with a unique intelligent technology platform that connects healthcare providers and their patients. Despite some macro headwinds and execution issues with a large client, OptimizeRx is poised for strong revenue growth in the high teens/low twenties, driven by the adoption of its AI-enabled DAAP, mid-tier and MedTech clients, and a transition to subscription-based revenue. While the FY26 guidance was lowered due to the client issue, there is potential for stronger financial performance in FY27.
Bears say
OptimizeRx is exposed to the impact of reductions in pharmareimbursement and budget restraints in biopharma, hindering its primarily life sciences-driven revenue. Any changes in regulations surrounding the marketing of prescription drugs could have negative consequences for its business model. Additionally, a recent CFO transition raises concerns about financial stability in the near future.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares